Article
Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
International journal of environmental research and public health - 28 Jan 2020
Liu Yin, Zhang Hui, Zhang Lei, Zou Xia, Ling Li
Abstract excerpt
We aimed to assess the cost-effectiveness of (1) treating acute hepatitis C virus (HCV) vs deferring treatment until the chronic phase and (2) treating all chronic patients vs only those with advanced fibrosis; among Chinese genotype 1b treatment-naïve patients who injected drugs (PWID), using a combination Daclatasvir (DCV) plus Asunaprevir (ASV) regimen and a Peg-interferon (PegIFN)-based regimen, respectively....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.